{'fraction_non_alphanumeric': 0.01752577319587629, 'fraction_numerical': 0.004123711340206186, 'mean_word_length': 5.5608108108108105, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pattern of proteolytic processing of Amyloid Precursor Protein in Down syndrome

Currently, it is estimated that 1 in 800 live births worldwide has Down syndrome (DS). In addition to the relationship with intellectual disability, DS is directly associated with a group of clinical manifestations resulting from premature aging, and may present patterns of comorbidities similar to those found in the elderly. Therefore, together with the greater number of years lived, there is an increased risk of developing Alzheimer's disease (AD) in DS, especially with regard to the interaction between pathogenic mechanisms related to cerebral amyloidogenesis and factors inherent to premature aging. Thus, this study aimed to investigate biological markers of AD in peripheral blood samples from adults and elderly individuals with DS and to compare them with individuals with normal karyotype, stratifying the groups according to the presence or absence of cognitive impairment.